<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00096525</url>
  </required_header>
  <id_info>
    <org_study_id>04-014</org_study_id>
    <secondary_id>MSKCC-04014</secondary_id>
    <nct_id>NCT00096525</nct_id>
  </id_info>
  <brief_title>Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer</brief_title>
  <official_title>Phase II Trial of CC-5013 in Patients With Advanced Renal Cell Carcinoma With Either No Prior Treatment or One Prior Treatment Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapy such as lenalidomide use different ways to stimulate the immune&#xD;
      system and stop tumor cells from growing. It may also stop the growth of tumor cells by&#xD;
      stopping blood flow to the tumor.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well lenalidomide works in treating patients&#xD;
      with advanced or unresectable kidney cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the best response in patients with advanced or unresectable renal cell cancer&#xD;
           treated with lenalidomide (CC-5013).&#xD;
&#xD;
        -  Determine the time to disease progression in patients treated with this drug.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the safety of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label study.&#xD;
&#xD;
      Patients receive oral lenalidomide (CC-5013) once daily on days 1-21. Courses repeat every 28&#xD;
      days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed at 30 days and then every 3 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 14-25 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <primary_completion_date type="Actual">August 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy (complete and partial response)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
  </secondary_outcome>
  <condition>Kidney Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lenalidomide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed renal cell carcinoma (RCC)&#xD;
&#xD;
               -  Advanced or unresectable disease&#xD;
&#xD;
          -  At least 1 measurable lesion&#xD;
&#xD;
          -  No active brain metastases&#xD;
&#xD;
               -  Prior brain metastases allowed provided patient has been treated with&#xD;
                  radiotherapy or surgery AND remains asymptomatic for ≥ 6 months&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
          -  AST and ALT ≤ 2 times upper limit of normal (ULN) (5 times ULN if liver metastases are&#xD;
             present)&#xD;
&#xD;
          -  No hepatitis A, B, or C infection&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 2.0 mg/dL&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No known hypersensitivity to thalidomide&#xD;
&#xD;
          -  No other serious medical condition, laboratory abnormality, or psychiatric illness&#xD;
             that would preclude giving informed consent&#xD;
&#xD;
          -  No other malignancy within the past 5 years except curatively treated basal cell or&#xD;
             squamous cell skin cancer, carcinoma in situ of the cervix or breast, localized&#xD;
             prostate cancer, or superficial bladder cancer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No more than 1 prior systemic immunotherapy regimen for RCC&#xD;
&#xD;
          -  No prior lenalidomide (CC-5013)&#xD;
&#xD;
          -  No prior or concurrent thalidomide&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No more than 1 prior systemic chemotherapy regimen for RCC&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No more than 1 prior systemic hormonal therapy regimen for RCC&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior surgery and recovered&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No more than 1 other prior systemic therapy regimen for RCC&#xD;
&#xD;
          -  No other concurrent anticancer therapies&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gnanamba V. Kondagunta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Patel PH, Kondagunta GV, Schwartz L, Ishill N, Bacik J, DeLuca J, Russo P, Motzer RJ. Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma. Invest New Drugs. 2008 Jun;26(3):273-6. Epub 2007 Dec 27.</citation>
    <PMID>18161005</PMID>
  </results_reference>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>November 9, 2004</study_first_submitted>
  <study_first_submitted_qc>November 9, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2004</study_first_posted>
  <last_update_submitted>January 15, 2013</last_update_submitted>
  <last_update_submitted_qc>January 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 17, 2013</last_update_posted>
  <keyword>recurrent renal cell cancer</keyword>
  <keyword>stage III renal cell cancer</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

